1
|
Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG. Part II: The treatment of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol 2024; 90:237-248. [PMID: 35809802 DOI: 10.1016/j.jaad.2022.05.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 05/15/2022] [Accepted: 05/25/2022] [Indexed: 10/17/2022]
Abstract
Raynaud phenomenon (RP) presents with either primary or secondary disease, and both have the potential to negatively impact patient quality of life. First-line management of RP should include lifestyle modifications in all patients. Some patients with primary RP and most with secondary RP require pharmacologic therapies, which may include calcium channel blockers, topical nitrates, phosphodiesterase 5 inhibitors, or endothelin antagonists. Additional approaches to treatment for those with signs of critical ischemia or those who fail pharmacologic therapy include botulinum toxin injection and digital sympathectomy. Herein, we describe in detail the treatment options for patients with RP as well as provide treatment algorithms for each RP subtype.
Collapse
Affiliation(s)
- Paul Curtiss
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
| | - Katerina Svigos
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
| | - Zachary Schwager
- Department of Dermatology, Lahey Hospital and Medical Center, Burlington, Massachusetts
| | - Kristen Lo Sicco
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
| | - Anrdew G Franks
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York; Division of Rheumatology, Department of Internal Medicine, New York University Grossman School of Medicine, New York, New York
| |
Collapse
|
2
|
Pușcașu C, Zanfirescu A, Negreș S, Șeremet OC. Exploring the Multifaceted Potential of Sildenafil in Medicine. Medicina (Kaunas) 2023; 59:2190. [PMID: 38138293 PMCID: PMC10744870 DOI: 10.3390/medicina59122190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 12/11/2023] [Accepted: 12/14/2023] [Indexed: 12/24/2023]
Abstract
Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and vasodilation. By targeting cGMP for degradation, PDE5 inhibits sustained vasodilation. PDE5 operates in diverse anatomical regions, with its upregulation linked to various pathologies, including cancer and neurodegenerative diseases. Sildenafil, a selective PDE5 inhibitor, is prescribed for erectile dysfunction and pulmonary arterial hypertension. However, considering the extensive roles of PDE5, sildenafil might be useful in other pathologies. This review aims to comprehensively explore sildenafil's therapeutic potential across medicine, addressing a gap in the current literature. Recognising sildenafil's broader potential may unveil new treatment avenues, optimising existing approaches and broadening its clinical application.
Collapse
Affiliation(s)
| | - Anca Zanfirescu
- Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania; (C.P.); (S.N.); (O.C.Ș.)
| | | | | |
Collapse
|
3
|
Liu L, Wang Q, Liao H, Ye J, Huang J, Li S, Peng H, Yu X, Wen H, Wang X. Soluble microneedle patch with photothermal and NO-release properties for painless and precise treatment of ischemic perforator flaps. J Mater Chem B 2021; 9:7725-7733. [PMID: 34586148 DOI: 10.1039/d1tb00491c] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Skin necrosis is the most serious complication of flap plastic surgery, which means the failure of the operation. Systemic administration rarely benefits the local area and can lead to side effects, while topical administration has poor permeability due to the skin barrier function. Currently, few of these common medical interventions can totally respond to the blood supply of the skin after surgery. Herein, a soluble microneedle (MN) patch made of hyaluronic acid was used to target the ischemic area in a painless and precise manner for transdermal drug delivery. Based on the important role of nitric oxide (NO) in angiogenesis, the thermosensitive NO donor (BNN6) and gold nanorods (GNRs) acting as photothermal agents were introduced into the microneedles (MNs). The hyperthermia induced by GNRs under near infrared (NIR, 808 nm) irradiation could enhance the penetration of drugs and facilitate NO release from BNN6. A series of corresponding experiments proved that the system played a significant promotion role in vascular regeneration, providing a painless, precise and NO-assisted treatment method for the ischemic perforator flaps.
Collapse
Affiliation(s)
- Lubing Liu
- Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China.
| | - Qingqing Wang
- The National Engineering Research Center for Bioengineering Drugs and the Technologies: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, China.
| | - Huaiwei Liao
- Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China.
| | - Jing Ye
- The National Engineering Research Center for Bioengineering Drugs and the Technologies: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, China.
| | - Jinjun Huang
- Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China.
| | - Shisheng Li
- Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China.
| | - Haichuan Peng
- The National Engineering Research Center for Bioengineering Drugs and the Technologies: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, China.
| | - Xiang Yu
- The National Engineering Research Center for Bioengineering Drugs and the Technologies: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, China.
| | - Huicai Wen
- Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China.
| | - Xiaolei Wang
- The National Engineering Research Center for Bioengineering Drugs and the Technologies: Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, China.
| |
Collapse
|
4
|
Abstract
BACKGROUND Numerous agents have been suggested for the symptomatic treatment of primary Raynaud's phenomenon. Apart from calcium channel blockers, which are considered to be the drugs of choice, evidence of the effects of alternative pharmacological treatments is limited. This is an update of a review first published in 2008. OBJECTIVES To assess the effects of drugs with vasodilator effects on primary Raynaud's phenomenon as determined by frequency, severity, and duration of vasospastic attacks; quality of life; adverse events; and Raynauds Condition Score. SEARCH METHODS The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases, and the World Health Organization International Clinical Trials Registry Platform and the ClinicalTrials.gov trial register to November 16, 2020. SELECTION CRITERIA We included randomized controlled trials evaluating effects of oral, intravenous, and topical formulations of any drug with vasodilator effects on subjective symptoms, severity scores, and radiological outcomes in primary Raynaud's phenomenon. Treatment with calcium channel blockers was not assessed in this review, nor were these agents compared. DATA COLLECTION AND ANALYSIS Two review authors independently selected studies for inclusion, assessed studies using the Cochrane "Risk of bias" tool, and extracted study data. Outcomes of interest included frequency, severity, and duration of attacks; quality of life (QoL); adverse events (AEs); and the Raynaud Condition Score (RCS). We assessed the certainty of the evidence using GRADE. MAIN RESULTS We identified seven new studies for this update. In total, we included 15 studies involving 635 participants. These studies compared different vasodilators to placebo. Individual studies used different methods and measures to report different outcomes. Angiotensin-converting enzyme (ACE) inhibitors Combining data from three studies revealed a possible small increase in the frequency of attacks per week after treatment (captopril or enalapril) compared to placebo (mean difference [MD] 0.79, 95% confidence interval [CI] 0.43 to 1.17; low-certainty evidence). There was no evidence of a difference between groups in severity of attacks (MD -0.17, 95% CI -4.66 to 4.31; 34 participants, 2 studies; low-certainty evidence); duration of attacks (MD 0.54, 95% CI -2.42 to 1.34; 14 participants, 1 study; low-certainty evidence); or AEs (risk ratio [RR] 1.35, 95% CI 0.67 to 2.73; 46 participants, 3 studies; low-certainty evidence). QoL and RCS were not reported. Alpha blockers Two studies used alpha blockers (buflomedil or moxisylyte). We were unable to combine data due to the way results were presented. Buflomedil probably reduced the frequency of attacks compared to placebo (MD -8.82, 95% CI -11.04 to -6.60; 31 participants, 1 study; moderate-certainty evidence) and may improve severity scores (MD -0.41, 95% CI -0.62 to -0.30; moderate-certainty evidence). With moxisylyte, investigators reported fewer attacks (P < 0.02), less severe symptoms (P < 0.01), and shorter duration of attacks, but the clinical relevance of these results is unclear. No evidence of a difference in AEs between buflomedil and placebo groups was noted (RR 1.41, 95% CI 0.27 to 7.28; 31 participants, 1 study; moderate-certainty evidence). More AEs were observed in participants in the moxisylyte group than in the placebo group. Prostaglandin/prostacyclin analogues One study compared beraprost versus placebo. There was no evidence of benefit for frequency (MD 2.00, 95% CI -0.35 to 4.35; 118 participants, low-certainty evidence) or severity (MD -0.06, 95% CI -0.34 to 0.22; 118 participants, low-certainty evidence) of attacks. Overall, more AEs were noted in the beraprost group (RR 1.59, 95% CI 1.05 to 2.42; 125 participants; low-certainty evidence). This study did not report on duration of attacks, QoL, or RCS. Thromboxane synthase inhibitors One study compared a thromboxane synthase inhibitor (dazoxiben) versus placebo. There was no evidence of benefit for frequency of attacks (MD 0.8, 95% CI -1.81 to 3.41; 6 participants; very low-certainty evidence). Adverse events were not reported in subgroup analyses of participants with primary Raynaud's phenomenon, and the study did not report on duration of attacks, severity of symptoms, QoL, or RCS. Selective serotonin reuptake inhibitors One study compared ketanserin with placebo. There may be a slight reduction in the number of attacks per week with ketanserin compared to placebo (MD -14.0, 95% CI -27.72 to -0.28; 41 participants; very low-certainty evidence) and reduced severity score (MD -133.00, 95% CI -162.40 to -103.60; 41 participants; very low-certainty evidence). There was no evidence that ketanserin reduced the duration of attacks (MD -4.00, 95% CI -14.82 to 6.82; 41 participants; very low-certainty evidence), or that AEs were increased in either group (RR 1.54, 95% CI 0.89 to 2.65; 41 participants; very low-certainty evidence). This study did not report on QoL or RCS. Nitrate/nitrate derivatives Four studies compared topical treatments of nitroglycerin or glyceryl trinitrate versus placebo, each reporting on limited outcomes. Meta-analysis demonstrated no evidence of effect on frequency of attacks per week (MD -1.57, 95% CI -4.31 to 1.17; 86 participants, 2 studies; very low-certainty evidence). We were unable to pool any data for the remaining outcomes. Phosphodiesterase inhibitors Three studies compared phosphodiesterase inhibitors (vardenafil, cilostazol or PF-00489791) to an equivalent placebo. Results showed no evidence of a difference in frequency of attacks (standardized MD [SMD] -0.05, 95% CI -6.71 to 6.61; 111 participants, 2 studies; low-certainty evidence), severity of attacks (MD -0.03, 95% CI -1.04 to 0.97; 111 participants, 2 studies; very low-certainty evidence), duration of attacks (MD -1.60, 95% CI -7.51 to 4.31; 73 participants, 1 study; low-certainty evidence), or RCS (SMD -0.8, 95% CI -1.74 to 0.13; 79 participants, 2 studies; low-certainty evidence). Study authors reported that 35% of participants on cilostazol complained of headaches, which were not reported in the placebo group. PF-00489791 caused 34 of 54 participants to experience AEs versus 43 of 102 participants receiving placebo (RR 1.49). Headache was most common, affecting 14 participants (PF-00489791) versus nine participants (placebo). AUTHORS' CONCLUSIONS The included studies investigated several different vasodilators (topical and oral) for treatment of primary Raynaud's phenomenon. Small sample sizes, limited data, and variability in outcome reporting yielded evidence of very low to moderate certainty. Evidence is insufficient to support the use of vasodilators and suggests that vasodilator use may even worsen disease.
Collapse
Affiliation(s)
- Kevin Yc Su
- Department of Rheumatology, Gold Coast University Hospital, Southport, Australia
| | - Meghna Sharma
- Department of Rheumatology, Gold Coast University Hospital, Southport, Australia
- School of Medicine, Bond University, Robina, Australia
| | - Hyunjun Jonathan Kim
- Department of Rheumatology, Gold Coast University Hospital, Southport, Australia
| | - Elizabeth Kaganov
- Department of Rheumatology, Gold Coast University Hospital, Southport, Australia
- School of Medicine, Bond University, Robina, Australia
| | - Ian Hughes
- Office for Research Governance and Development, Gold Coast University Hospital, Southport, Australia
- School of Medicine, The University of Queensland, St Lucia, Australia
| | | | - Jennifer Hwee Kwoon Ng
- Department of Rheumatology, Gold Coast University Hospital, Southport, Australia
- School of Medicine, Griffith University, Gold Coast Campus, Southport, Australia
| |
Collapse
|
5
|
Pintea Bentea G, Wauters A, Wautrecht JC, Cogan E. Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients. Vasc Med 2020; 25:559-568. [PMID: 32990196 DOI: 10.1177/1358863x20953901] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Recent studies suggest the use of topical nitroglycerin (NTG) application in systemic sclerosis (SSc)-associated Raynaud phenomenon (RP). With the current study, we aimed to characterize for the first time the microvascular response to a NTG patch (Trinipatch® 5 mg/24 h) applied to the hand dorsum in patients with SSc using Laser Doppler imaging (LDI) at baseline and following a cold challenge. The study included 21 patients with SSc and 13 controls. Blood flow was evaluated by LDI at the level of the fingertips and metacarpus. Microvascular morphology was evaluated by nailfold capillaroscopy (NC). LDI revealed decreased fingertip baseline perfusion and a stronger vasoconstrictor response to a cold challenge in patients with SSc versus control. Metacarpal application of a NTG patch led to an increase in blood flow and hand temperature in patients with SSc. Furthermore, NTG administration led to a faster reperfusion after cold challenge. Correlation analyses revealed that the magnitude of the vasodilatory response was inversely related to baseline fingertip perfusion and hand temperature, but unrelated to the number of capillaries/mm assessed using NC. In conclusion, we provide evidence of a vasodilatory reaction following NTG patch application in patients with SSc using LDI and a protective effect against cold challenge. The magnitude of the response to NTG was related to functional, but not structural features. Our results support a further evaluation of the NTG patch as a possible therapeutic agent in SSc-associated RP.
Collapse
Affiliation(s)
| | - Aurélien Wauters
- Department of Cardiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-Claude Wautrecht
- Department of Cardiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Elie Cogan
- Department of Cardiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
6
|
Yalçın KS, Koşar A. The frequency of Raynaud’s phenomenon in patients with methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia. Turk J Med Sci 2019; 49:1444-1449. [PMID: 31651110 PMCID: PMC7018243 DOI: 10.3906/sag-1903-206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 07/22/2019] [Indexed: 12/30/2022] Open
Abstract
Background/aim Raynaud’s phenomenon (RP) is not a rare health problem; global prevalence is about 3%–20%. Etiology and pathophysiology of this pathology has not been clarified. There are many precipitating factors resulting in RP. Hyperhomocysteinemia resulting from methylenetetrahydrofolate reductase (MTHFR) gene mutationmay have a role in its etiology. The aim of this study was to observe the frequency of RP in patients with MTFHR gene mutation and hyperhomocysteinemia. Possible relationships among vitamin B12, folic acid, complete blood count (leukocytes and platelets), and c-reactive protein levels and RP were also analyzed. Materials and methods A total of 388 patients admitted to the internal medicine, hematology, and obstetric clinics of a university hospital between January 2012 and April 2013 ranging in age from 21 to 83 (mean age 38.16 ± 13.1) were enrolled in the study. Eighty-five (21.9%) of the patients were male and 303 (78.1%) were female. MTHFR gene mutation was analyzed in 388 patients; 52 (13.4%) were homozygous, 275 (70.9%) were heterozygous, and 61 (15.7%) were found to be negative for the MTHFR gene mutation and accepted as a control group. Vitamin B12, folic acid, complete blood count (leukocytes and platelets), and c-reactive protein levels were also analyzed. Results Homocysteine levels were higher in both heterozygous and homozygous groups (P < 0.05). RP was more frequently observed in patients with elevated homocysteine levels (P < 0.05; X2 = 14.51). There was no significant relationship in other parameters studied. Conclusion RP was more frequently observed in the groups with the MTHFR mutation and hyperhomocysteinemia. Serum homocysteine levels in patients with RP may be helpful for diagnosis.
Collapse
Affiliation(s)
- Kadir Serkan Yalçın
- Department of Internal Diseases, Lokman Hekim Ankara Hospital, Ankara, Turkey
| | - Ali Koşar
- Department of Hematology, Lokman Hekim Ankara Hospital, Ankara, Turkey
| |
Collapse
|
7
|
Md Yusof MY, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, Vital EM. Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus. Lupus 2019; 28:1320-1328. [PMID: 31522626 DOI: 10.1177/0961203319873977] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES The objectives of this study were to assess the reliability of a novel objective outcome measure, laser Doppler imaging (LDI), its validity against skin biopsy histology and other clinical instruments, including localized cutaneous lupus disease area and severity index (L-CLASI) and visual analogue scale (VAS) score of photographs, and its responsiveness to clinical change with therapy. METHODS A prospective observational cohort study was conducted in 30 patients with active cutaneous lupus erythematosus (CLE). At baseline and 3 months, disease activity was assessed using L-CLASI and a high resolution LDI system by two assessors. Skin biopsy was scored as 0 = non-active, 1 = mild activity and 2 = active. Photographs were assessed by two clinicians using 100 mm VAS. Inter-rater reliability was analyzed using Bland-Altman limits of agreement. Correlation between histology and LDI, L-CLASI and VAS and sensitivity to change of LDI with physician subjective assessment of change (PSAC) at 3 months were analyzed using Kendall's tau-a. RESULTS Of 30 patients with CLE, 28 (93%) were female, mean (SD) age 48.4 (11.5) y, 25 (83%) were Caucasians, 25 (83%) had concurrent systemic lupus erythematosus and 16 (53%) were smokers. CLE subtypes were acute = 9, subacute = 8 and chronic = 13. Inter-rater agreement for LDI was fair but for VAS score of photographs was poor. In 20 patients with biopsy, correlation with histology was better for LDI (tau-a = 0.53) than L-CLASI (tau-a = 0.26) (difference = 0.27; 90% CI 0.05-0.49) or VAS score of photographs (tau-a = 0.17) (difference = 0.36; 90% CI 0.04-0.68). There was a moderate correlation between PSAC score and change in LDI (tau-a = 0.56; 90% CI 0.38-0.74; p < 0.001, n = 15). CONCLUSION LDI provides a reliable, valid and responsive quantitative measure of inflammation in CLE. It has a better correlation with histology compared to clinical instruments. LDI provides an objective outcome measure for clinical trials.
Collapse
Affiliation(s)
- M Y Md Yusof
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - J Britton
- Department of Medical Physics, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - S Edward
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds UK
| | - E M A Hensor
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - M J Goodfield
- NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds UK
| | - P M Laws
- Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds UK
| | - P Emery
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - M Wittmann
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - E M Vital
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
8
|
Shepherd AI, Costello JT, Bailey SJ, Bishop N, Wadley AJ, Young-Min S, Gilchrist M, Mayes H, White D, Gorczynski P, Saynor ZL, Massey H, Eglin CM. "Beet" the cold: beetroot juice supplementation improves peripheral blood flow, endothelial function, and anti-inflammatory status in individuals with Raynaud's phenomenon. J Appl Physiol (1985) 2019; 127:1478-1490. [PMID: 31343948 DOI: 10.1152/japplphysiol.00292.2019] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Raynaud's phenomenon (RP) is characterized by recurrent transient peripheral vasospasm and lower nitric oxide (NO) bioavailability in the cold. We investigated the effect of nitrate-rich beetroot juice (BJ) supplementation on 1) NO-mediated vasodilation, 2) cutaneous vascular conductance (CVC) and skin temperature (Tsk) following local cooling, and 3) systemic anti-inflammatory status. Following baseline testing, 23 individuals with RP attended four times, in a double-blind, randomized crossover design, following acute and chronic (14 days) BJ and nitrate-depleted beetroot juice (NDBJ) supplementation. Peripheral Tsk and CVC were measured during and after mild hand and foot cooling, and during transdermal delivery of acetylcholine and sodium nitroprusside. Markers of anti-inflammatory status were also measured. Plasma nitrite concentration ([nitrite]) was increased in the BJ conditions (P < 0.001). Compared with the baseline visit, thumb CVC was greater following chronic-BJ (Δ2.0 flux/mmHg, P = 0.02) and chronic-NDBJ (Δ1.45 flux/mmHg, P = 0.01) supplementation; however, no changes in Tsk were observed (P > 0.05). Plasma [interleukin-10] was greater, pan endothelin and systolic and diastolic blood pressure (BP) were reduced, and forearm endothelial function was improved, by both BJ and NDBJ supplementation (P < 0.05). Acute and chronic BJ and NDBJ supplementation improved anti-inflammatory status, endothelial function and blood pressure (BP). CVC following cooling increased post chronic-BJ and chronic-NDBJ supplementation, but no effect on Tsk was observed. The key findings are that beetroot supplementation improves thumb blood flow, improves endothelial function and anti-inflammatory status, and reduces BP in people with Raynaud's.NEW & NOTEWORTHY This is the first study to examine the effect of dietary nitrate supplementation in individuals with Raynaud's phenomenon. The principal novel findings from this study were that both beetroot juice and nitrate-depleted beetroot juice 1) increased blood flow in the thumb following a cold challenge; 2) enhanced endothelium-dependent and -independent vasodilation in the forearm; 3) reduced systolic and diastolic blood pressure, and pan-endothelin concentration; and 4) improved inflammatory status in comparison to baseline.
Collapse
Affiliation(s)
- Anthony I Shepherd
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Joseph T Costello
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Stephen J Bailey
- National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Epinal Way, Loughborough, United Kingdom
| | - Nicolette Bishop
- National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Epinal Way, Loughborough, United Kingdom.,University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, United Kingdom
| | - Alex J Wadley
- National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Epinal Way, Loughborough, United Kingdom.,University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, United Kingdom
| | - Steven Young-Min
- Rheumatology Department, Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom
| | - Mark Gilchrist
- University of Exeter Medical School and NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom
| | - Harry Mayes
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Danny White
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Paul Gorczynski
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Zoe L Saynor
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Heather Massey
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| | - Clare M Eglin
- School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom
| |
Collapse
|
9
|
Affiliation(s)
- Nathan S. Bryan
- Department of Molecular and Human GeneticsBaylor College of Medicine One Baylor Plaza Alkek Building for Biomedical Research R-850 Houston TX 77030
| |
Collapse
|
10
|
Liu F, de Ruyter EM, Athorn RZ, Brewster CJ, Henman DJ, Morrison RS, Smits RJ, Cottrell JJ, Dunshea FR. Effects of L-citrulline supplementation on heat stress physiology, lactation performance and subsequent reproductive performance of sows in summer. J Anim Physiol Anim Nutr (Berl) 2018; 103:251-257. [PMID: 30485568 DOI: 10.1111/jpn.13028] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 10/16/2018] [Accepted: 11/01/2018] [Indexed: 01/08/2023]
Abstract
Lactating sows are susceptible to heat stress (HS). Part of the thermoregulatory response to HS is to increase peripheral blood flow, which is mediated in part by the vasodilator, nitric oxide (NO). Therefore, the aim of this experiment was to determine the effect of supplementation of L-citrulline, a NO precursor, on symptoms of HS, lactation performance and subsequent reproductive performance of sows in summer. A total of 221 summer farrowing mixed parity sows were fed either a control diet or supplemented with 1% L-citrulline upon entry to the farrowing house (6 ± 1.8 days for mean ± standard deviation [SD] before farrowing) until weaning (26 ± 1.5 days). The average daily minimum and maximum temperature in the farrowing house was 21.0 ± 1.88 and 29.2 ± 3.82°C (mean ± SD). Rectal temperature, respiration rate, and plasma and urinary nitrite and nitrate (NOx) of sows were measured on the 19th day post-farrowing. Supplemental L-citrulline in the diet did not affect the number of piglets born alive, feed intake of sows, body weight or backfat thickness of sows at weaning, or litter weight gain. L-citrulline tended to reduce piglet pre-weaning mortality rate from 18.6% to 15.6% (p = 0.058). L-citrulline reduced the respiration rate of sows compared to the control diet at 17:00 hr (Time × Diet, p < 0.001); however, rectal temperature was not affected. L-citrulline tended to increase urinary NOx concentrations (127 vs. 224 µM, p = 0.057) but not plasma NOx concentrations. L-citrulline did not affect farrowing rate or number of piglets born alive in the subsequent parity. In conclusion, L-citrulline supplementation reduced respiration rate of lactating sows and reduced piglet pre-weaning mortality rate in summer. Whether the effects were due to a NO-dependent mechanism requires further validation.
Collapse
Affiliation(s)
- Fan Liu
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Emily M de Ruyter
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Rebecca Z Athorn
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Chris J Brewster
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - David J Henman
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Rebecca S Morrison
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Robert J Smits
- Research and Innovation, Rivalea Australia Pty Ltd, Corowa, New South Wales, Australia
| | - Jeremy J Cottrell
- Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, Australia
| | - Frank R Dunshea
- Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
11
|
Qiu O, Chan T, Luen M, Cruz JE, Hermes-desantis ER. Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review. Rheumatol Int 2018; 38:2209-16. [DOI: 10.1007/s00296-018-4119-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 08/02/2018] [Indexed: 10/28/2022]
|
12
|
Edmonds ME, Bodansky HJ, Boulton AJM, Chadwick PJ, Dang CN, D'Costa R, Johnston A, Kennon B, Leese G, Rajbhandari SM, Serena TE, Young MJ, Stewart JE, Tucker AT, Carter MJ. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen 2018; 26:228-237. [PMID: 29617058 DOI: 10.1111/wrr.12630] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 03/26/2018] [Indexed: 12/24/2022]
Abstract
The aim of this multicenter, prospective, observer-blinded, parallel group, randomized controlled trial was to assess the safety and efficacy of EDX110, a nitric oxide generating medical device, in the treatment of diabetic foot ulcers in a patient group reflecting "real world" clinical practice compared against optimal standard care. Participants were recruited from ten hospital sites in multidisciplinary foot ulcer clinics. The ulcers were full thickness, with an area of 25-2,500 mm2 and either a palpable pedal pulse or ankle brachial pressure index > 0.5. Infected ulcers were included. Treatment lasted 12 weeks, or until healed, with a 12-week follow-up period. Both arms were given optimal debridement, offloading and antimicrobial treatment, the only difference being the fixed used of EDX110 as the wound dressing in the EDX110 group. 135 participants were recruited with 148 ulcers (EDX110-75; Control-73), 30% of which were clinically infected at baseline. EDX110 achieved its primary endpoint by attaining a median Percentage Area Reduction of 88.6% compared to 46.9% for the control group (p = 0.016) at 12 weeks in the intention-to-treat population. There was no significant difference between wound size reduction achieved by EDX110 after 4 weeks and the wound size reduction achieved in the control group after 12 weeks. EDX110 was well tolerated. Thirty serious adverse events were reported (12 in the EDX110 group, of which 4 were related to the ulcer; 18 in the control group, of which 10 were related and 1 possibly related to the ulcer), with significant reduction in serious adverse events related to the ulcer in EDX group. There was no significant difference in adverse events. This study, in a real world clinical foot ulcer population, demonstrates the ability of EDX110 to improve healing, as measured by significantly reducing the ulcer area, compared to current best clinical practice.
Collapse
Affiliation(s)
- Michael E Edmonds
- Diabetic Foot Clinic, King's College Hospital, London, United Kingdom
| | - Harvey J Bodansky
- Diabetes Centre, St James's University Hospital, Leeds, West Yorkshire, United Kingdom
| | - Andrew J M Boulton
- Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, United Kingdom
| | - Paul J Chadwick
- Podiatry and Foot Health, Salford Royal Hospital (NHS) Foundation Trust, Salford, United Kingdom
| | - Cuong N Dang
- Diabetes Centre, North Manchester General Hospital, Manchester, United Kingdom
| | - Ryan D'Costa
- Diabetes Centre, Pinderfields Hospital, Wakefield, United Kingdom
| | - Atholl Johnston
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Brian Kennon
- Diabetes Centre, Queen Elizabeth University Hospital, Glasgow, United Kingdom
| | - Graham Leese
- Diabetes Clinic, Ninewells Hospital, Dundee, United Kingdom
| | - Satyan M Rajbhandari
- Diabetes Centre, Chorley & South Ribble Hospital, Preston Road, University of Central Lancashire, Chorley, United Kingdom
| | | | - Matthew J Young
- Diabetic Foot Clinic, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
| | - Joanne E Stewart
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Arthur T Tucker
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | | |
Collapse
|
13
|
Wortsman X, Del Barrio-Díaz P, Meza-Romero R, Poehls-Risco C, Vera-Kellet C. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study. J Am Acad Dermatol 2018; 78:189-190. [PMID: 29241781 DOI: 10.1016/j.jaad.2017.08.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Revised: 07/16/2017] [Accepted: 08/08/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Ximena Wortsman
- Institute for Diagnostic Imaging and Research of the Skin and Soft Tissues, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Pablo Del Barrio-Díaz
- Department of Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Rodrigo Meza-Romero
- Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | | | - Cristián Vera-Kellet
- Connective Tissue Diseases Unit, Department of Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| |
Collapse
|
14
|
Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol 2018; 78:1110-1118.e3. [DOI: 10.1016/j.jaad.2018.01.043] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 01/21/2018] [Accepted: 01/27/2018] [Indexed: 12/14/2022]
|
15
|
Lourenço SDM, de Oliveira MG. Topical photochemical nitric oxide release from porous poly(vinyl alcohol) membrane for visible light modulation of dermal vasodilation. J Photochem Photobiol A Chem 2017. [DOI: 10.1016/j.jphotochem.2017.06.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
16
|
Suschek CV, Opländer C. The application of cold atmospheric plasma in medicine: The potential role of nitric oxide in plasma-induced effects. Clinical Plasma Medicine 2016; 4:1-8. [DOI: 10.1016/j.cpme.2016.05.001] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
17
|
Latuskiewicz-Potemska J, Chmura-Skirlinska A, Gurbiel RJ, Smolewska E. Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome. Clin Rheumatol 2016; 35:1993-2001. [PMID: 27357717 DOI: 10.1007/s10067-016-3340-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 06/19/2016] [Accepted: 06/21/2016] [Indexed: 01/01/2023]
Abstract
Raynaud syndrome (RS) manifests as episodes of transient spasms of peripheral blood vessels, most often in response to cold. The reason of that symptom (primary RS (pRS)) usually cannot be found but may be accompanied by some autoimmune diseases (secondary RS (sRS)). In this study, we assessed microcapillary status and serum concentrations of chosen cytokines, adhesive molecules, and nitric oxide (NO) in patients with pRS and sRS in comparison with healthy children. Eighty-six patients with RS were enrolled into the study, including 52 with pRS and 34 with sRS. The control group consisted of 29 healthy children. A decrease in myorelaxative and anticoagulant abilities was observed, with simultaneous prevalence of vasopressor substances and procoagulative activity. Therefore, several important factors such as endothelin-1 (ET-1), E-selectin (E-sel), interleukin-18 (IL-18), and nitrogen oxide (NO) were also analyzed. Two types of capillaroscopy status were determined: normal and microangiopathic. There was a significant relationship between presence of microangiopathy and higher serum ET-1 (p = 0.018) and E-sel (p = 0.021) levels. Similarly, we have found a correlation between presence of ANA and higher ET-1 (p = 0.005), but not E-sel (p = 0.241). In patients with pRS, we found significant relationship between ANA and higher ET-1 (p = 0.008). No such relations were observed in sRS patients. Our data indicates that external factor-induced vasoconstrictive effects dominated in pRS, whereas in sRS in the course of connective tissue diseases, it was accompanied by coexistent vasodilation due to endothelial dysfunction. The latter phenomenon is at least partially dependent on insufficient NO release.
Collapse
Affiliation(s)
| | - Antonina Chmura-Skirlinska
- Laboratory of EPR Spectroscopy, Jagiellonian Centre for Experimental Therapeutic, Jagiellonian University in Krakow, 14 Bobrzynskiego St, 30-348, Krakow, Poland
| | - Ryszard J Gurbiel
- Laboratory of EPR Spectroscopy, Jagiellonian Centre for Experimental Therapeutic, Jagiellonian University in Krakow, 14 Bobrzynskiego St, 30-348, Krakow, Poland.,Department of Molecular Biophysics, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University in Krakow, 7 Gronostajowa St, 30-387, Krakow, Poland
| | - Elzbieta Smolewska
- Department of Pediatric Rheumatology, Medical University of Lodz, 36/50 Sporna St, 91-738, Lodz, Poland.
| |
Collapse
|
18
|
Ganzarolli de Oliveira M. S-Nitrosothiols as Platforms for Topical Nitric Oxide Delivery. Basic Clin Pharmacol Toxicol 2016; 119 Suppl 3:49-56. [PMID: 27030007 DOI: 10.1111/bcpt.12588] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2016] [Accepted: 03/16/2016] [Indexed: 01/07/2023]
Abstract
Nitric oxide (NO) is a small radical species involved in several fundamental physiological processes, including the control of vascular tone, the immune response and neuronal signalling. Endothelial dysfunction with the decreased NO bioavailability is the underlying cause of several diseases and has led to the development of a wide range of systemic NO donor compounds to lower the blood pressure and control hypertensive crises. However, several potential therapeutic actions of NO, not related to the cardiovascular system, demand exclusively local actions. Primary S-nitrosothiols (RSNOs) are endogenously found NO carriers and donors and have emerged as platforms for the localized delivery of NO in topical applications. Formulations for this purpose have evolved from low molecular weight RSNOs incorporated in polymeric films, hydrogels and viscous vehicles, to polymeric RSNOs where the SNO moiety is covalently bound to the polymer backbone. The biological actions displayed by these formulations include the increase in dermal vasodilation, the acceleration of wound healing, the killing of infectious microorganisms and an analgesic action against inflammatory pain. This MiniReview focuses on the state of the art of experimental topical formulations for NO delivery based on S-nitrosothiols and their potential therapeutic applications.
Collapse
|
19
|
Mazzotta C, Romano E, Bruni C, Manetti M, Lepri G, Bellando-Randone S, Blagojevic J, Ibba-Manneschi L, Matucci-Cerinic M, Guiducci S. Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. Arthritis Res Ther 2015; 17:221. [PMID: 26292963 PMCID: PMC4546224 DOI: 10.1186/s13075-015-0749-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 08/10/2015] [Indexed: 01/13/2023] Open
Abstract
Introduction The vascular and nervous systems have several anatomic and molecular mechanism similarities. Emerging evidence suggests that proteins involved in transmitting axonal guidance cues, including members of class III semaphorin (Sema3) family, play a critical role in blood vessel guidance during physiological and pathological vascular development. Sema3E is a natural antiangiogenic molecule that causes filopodial retraction in endothelial cells, inhibiting cell adhesion by disrupting integrin-mediated adhesive structures. The aim of the present study was to investigate whether in systemic sclerosis (SSc) Plexin-D1/Sema3E axis could be involved in the dysregulation of vascular tone control and angiogenesis. Methods Sema3E levels were measured by quantitative colorimetric sandwich ELISA in serum samples from 48 SSc patients, 45 subjects with primary Raynaud's phenomenon (pRP) and 48 age-matched and sex-matched healthy controls. Immunofluorescence staining on skin sections from 14 SSc patients and 12 healthy subjects was performed to evaluate Sema3E and Plexin-D1 expression. Western blotting was used to assess Plexin-D1/Sema3E axis in human SSc and healthy dermal microvascular endothelial cells (SSc-MVECs and H-MVECs, respectively) at basal condition and after stimulation with recombinant human vascular endothelial growth factor (VEGF), SSc and healthy sera. Capillary morphogenesis on Matrigel was performed on H-MVECs treated with healthy, pRP or SSc sera in the presence of Sema3E and Plexin-D1 soluble peptides. Results Serum Sema3E levels were significantly higher both in pRP subjects and SSc patients than in controls. In SSc, Sema3E levels were significantly increased in patients with early nailfold videocapillaroscopy (NVC) pattern compared to active/late patterns and pRP, and in patients without digital ulcers versus those with ulcers. In SSc skin, Sema3E expression was strongly increased in the microvascular endothelium. Cultured SSc-MVECs showed higher levels of phosphorylated Plexin-D1 and Sema3E expression than H-MVECs, and stimulation with SSc sera increased phosphorylated Plexin-D1 and Sema3E in H-MVECs. The addition of Sema3E-binding Plexin-D1 soluble peptide significantly attenuated the antiangiogenic effect of SSc sera on H-MVECs. Conclusions Our findings suggest that Plexin-D1/Sema3E axis is triggered in SSc endothelium and may have a role in the dysregulation of angiogenesis and vascular tone control by inducing neuro-vascular mechanism alterations clinically evident in particular in the early disease phases.
Collapse
Affiliation(s)
- Celestina Mazzotta
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Eloisa Romano
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Cosimo Bruni
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Mirko Manetti
- Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Largo Brambilla 3, I-50134, Florence, Italy.
| | - Gemma Lepri
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Silvia Bellando-Randone
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Jelena Blagojevic
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Lidia Ibba-Manneschi
- Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Largo Brambilla 3, I-50134, Florence, Italy.
| | - Marco Matucci-Cerinic
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| | - Serena Guiducci
- Department of Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Viale Pieraccini 18, I-50139, Florence, Italy.
| |
Collapse
|
20
|
Minniti CP, Gorbach AM, Xu D, Hon YY, Delaney KM, Seidel M, Malik N, Peters-Lawrence M, Cantilena C, Nichols JS, Mendelsohn L, Conrey A, Grimes G, Kato GJ. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. Lancet Haematol 2014; 1:e95-e103. [PMID: 25938131 DOI: 10.1016/s2352-3026(14)00019-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Well-tolerated and effective treatments are needed for chronic leg ulcers in sickle cell anaemia. Topical sodium nitrite, a known nitric oxide donor, enhances blood flow in ulcers and has known bacteriostatic effects. We aimed to assess the safety, tolerability, and pharmacokinetics of topical sodium nitrite in patients with sickle cell disease and chronic leg ulcers. METHODS We enrolled adult patients from an ambulatory clinic at the National Institutes of Health (Bethesda, MD, USA) with sickle cell anaemia with leg ulcers (with a surface area of 2.5-100 cm2) persisting for at least 4 weeks into a safety and tolerability phase 1 dose-escalation trial of topical sodium nitrite. Increasing concentrations of sodium nitrite cream were applied twice weekly for 4 weeks to one ulcer per patient at five dose levels (0.5%, 1%, 1.5%, 1.8%, and 2%). The primary endpoints were safety and tolerability, with secondary endpoints of pharmacokinetics, blood flow, and wound healing. Pain relief was analysed post hoc. Endpoints were analysed over time for the whole study population and according to dose level. This study is registered with ClinicalTrials.gov, number NCT01316796. FINDINGS Between April 4, 2011, and March 19, 2013, we enrolled 18 adult patients with sickle cell anaemia and leg ulcers into our trial. We assigned three patients into each cohort, and each cohort was treated with a different concentration of sodium nitrite cream (cohort 1: 0.5%, cohort 2: 1.0%, cohort 3: 1.5%, and cohort 4: 2.0%). Patients were not enrolled into the next cohort dose until we were able to establish that no dose-limiting toxicities were observed. An additional six patients were enrolled to cohort 3a: 1.8%, after two patients in cohort 4 had asymptomatic drops in diastolic blood pressure. No grade 3-4 adverse events were observed, and there were no serious adverse events or dose-limiting side-effects. Pharmacokinetic analysis showed that systemic absorption of sodium nitrite was very low. Application of topical sodium nitrite was associated with a significant increase in peri-wound cutaneous blood flow measured by laser speckle contrast imaging (p=0.0002), corroborated by increased peri-wound skin temperature by infrared thermography (p=0.0119). We recorded a dose-dependent decrease in leg ulcer size (p=0.0012) and pain (p<0.0001). Ulcers healed completely in three patients who received the highest concentrations of topical sodium nitrite (the 1.8% and 2% cream). In our post-hoc analysis of pain, brief pain inventory scores improved in pain severity (p=0.0048) and pain interference (p=0.0013). INTERPRETATION Our results indicate that topical sodium nitrite 2% cream is suitable for additional clinical trials in adults with sickle cell anaemia to promote healing of leg ulcers. FUNDING National Heart, Lung and Blood Institute Division of Intramural Research (National Institutes of Health).
Collapse
Affiliation(s)
- Caterina P Minniti
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Alexander M Gorbach
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Dihua Xu
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Yuen Yi Hon
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Kara-Marie Delaney
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Miles Seidel
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Nitin Malik
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Marlene Peters-Lawrence
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Carly Cantilena
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - James S Nichols
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Laurel Mendelsohn
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Anna Conrey
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - George Grimes
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| | - Gregory J Kato
- National Heart, Lung and Blood Institute (Prof C P Minniti MD, D Xu PhD, K-M Delaney MD, M Peters-Lawrence RN, C Cantilena BS, J S Nichols RN, L Mendelsohn BS, A Conrey NP, Prof G J Kato MD), Pharmaceutical Development Services, Clinical Center Pharmacy Department (Y Y Hon PharmD, G Grimes PharmD), and Infrared and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering (A M Gorbach PhD, M Seidel BS, N Malik BS), National Institutes of Health, Bethesda, MD, USA; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA (Prof G J Kato)
| |
Collapse
|
21
|
Marcilli RHM, de Oliveira MG. Nitric oxide-releasing poly(vinyl alcohol) film for increasing dermal vasodilation. Colloids Surf B Biointerfaces 2013; 116:643-51. [PMID: 24315855 DOI: 10.1016/j.colsurfb.2013.10.036] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Revised: 09/27/2013] [Accepted: 10/22/2013] [Indexed: 12/01/2022]
Abstract
Pathological conditions associated with the impairment of nitric oxide (NO) production in the vasculature, such as Raynaud's syndrome and diabetic angiopathy, have stimulated the development of new biomaterials capable of delivering NO topically. With this purpose, we modified poly(vinyl-alcohol) (PVA) by chemically crosslinking it via esterification with mercaptosuccinic acid. This reaction allowed the casting of sulfhydrylated PVA (PVA-SH) films. Differential scanning calorimetry and X-ray diffractometry showed that the crosslinking reaction completely suppressed the crystallization of PVA, leading to a non-porous film with a homogeneous distribution of -SH groups. The remaining free hydroxyl groups in the PVA-SH network conferred partial hydrophylicity to the material, which was responsible for a swelling degree of ca. 110%. The PVA-SH films were subjected to an S-nitrosation reaction of the -SH groups, yielding a PVA containing S-nitrosothiol groups (PVA-SNO). Amperometric and chemiluminescence measurements showed that the PVA-SNO films were capable of releasing NO spontaneously after immersion in physiological medium. Laser Doppler-flowmetry, used to assess the blood flow in the dermal microcirculation, showed that the topical application of hydrated PVA-SNO films on the health skin led to a dose- and time-dependent increase of more than 5-fold in the dermal baseline blood flow in less than 10min, with a prolonged action of more than 4h during continuous application. These results show that PVA-SNO films might emerge as a new material with potential for the topical treatment of microvascular skin disorders.
Collapse
Affiliation(s)
- Raphael H M Marcilli
- Institute of Chemistry, University of Campinas, UNICAMP, Campinas, 13083-970, SP, Brazil
| | - Marcelo G de Oliveira
- Institute of Chemistry, University of Campinas, UNICAMP, Campinas, 13083-970, SP, Brazil.
| |
Collapse
|
22
|
Farsaei S, Khalili H, Farboud ES, Khazaeipour Z. Sildenafil in the treatment of pressure ulcer: a randomised clinical trial. Int Wound J 2013; 12:111-7. [PMID: 23731453 DOI: 10.1111/iwj.12104] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2013] [Accepted: 04/29/2013] [Indexed: 12/12/2022] Open
Abstract
Pressure ulcer (PrU)-related hospitalisation and mortality are critical issues in medical and surgical patients. Although animal studies have suggested the beneficial effects of sildenafil on wound healing, related clinical data are lacking. This is the first clinical study that has evaluated the effects of topical sildenafil on PrU healing in human subjects. Enrolled patients were randomly allocated to receive topical sildenafil (10%) ointment or placebo daily. Wound healing was assessed visually and photographically by the change in wound score according to two-digit Stirling scale. Decreases in grades of the PrUs were significantly higher in sildenafil group compared with placebo group (P < 0·001). In addition, surface areas of ulcers in sildenafil group were significantly reduced compared to the control group at day 14 of intervention (P = 0·007). It appears that these effects may be mediated by improvement of microvascular reperfusion in the skin and soft tissue. Further study to emphasise the role of topical sildenafil in the prevention or treatment of PrUs in hospitalised patients is required.
Collapse
Affiliation(s)
- Shadi Farsaei
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | |
Collapse
|
23
|
Bernatchez SF, Menon V, Stoffel J, Walters SAH, Lindroos WE, Crossland MC, Shawler LG, Crossland SP, Boykin JV. Nitric oxide levels in wound fluid may reflect the healing trajectory. Wound Repair Regen 2013; 21:410-7. [DOI: 10.1111/wrr.12048] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Accepted: 01/30/2013] [Indexed: 02/04/2023]
Affiliation(s)
| | - Vinod Menon
- 3M Health Care; 3M Company; St. Paul; Minnesota
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Yamakoshi Y, Kotani K, Taniguchi N, Miwa T. Characterization of skin dermis microcirculation in flow-mediated dilation using optical sensor with pressurization mechanism. Med Biol Eng Comput 2013; 51:497-505. [PMID: 23274949 DOI: 10.1007/s11517-012-1017-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Accepted: 12/17/2012] [Indexed: 11/24/2022]
Abstract
Blood flows out of microvessels in the dermis when pressure higher than arterial blood pressure is applied to the fingertip, and subsequently re-flows into the microcirculation when pressure is released. Both the blood outflow and the reflow characteristics of microcirculation under pressurization are associated with microvasculature, blood and blood pressure. This study describes a novel method of measuring blood inflow and outflow characteristics of dermis microcirculation. An optical sensor, which is furnished with a 571 nm wavelength light source and a photodetector, is pressed to the skin surface using a pressure higher than the human subject's systolic arterial pressure. Hemoglobin concentration by change of the blood flow amount is estimated by the Beer-Lambert law. This method is applied to the measurement of blood inflow and outflow characteristics of microcirculation caused by reactive hyperemia after ischemia with duration of 5 min. Among three parameters evaluated, the one relating to the amplitude of pulsation shows a close correlation with conventional plethysmography, while the other two show varying time responses. Our method provides a new and useful insight into pathophysiology in health and disease conditions and may help researchers better understand the underlying mechanisms of numerous microcirculation-influenced diseases and medical conditions.
Collapse
Affiliation(s)
- Yoshiki Yamakoshi
- Faculty of Engineering, Gunma University, 1-5-1 Tenjincho, Kiryu 376-8515, Japan.
| | | | | | | |
Collapse
|
25
|
Opländer C, Müller T, Baschin M, Bozkurt A, Grieb G, Windolf J, Pallua N, Suschek CV. Characterization of novel nitrite-based nitric oxide generating delivery systems for topical dermal application. Nitric Oxide 2012; 28:24-32. [PMID: 23036613 DOI: 10.1016/j.niox.2012.09.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Revised: 09/21/2012] [Accepted: 09/24/2012] [Indexed: 12/11/2022]
Abstract
Topical application of nitric oxide (NO) has been shown to exert beneficial effects in the therapy of chronic wounds, impaired microcirculation, and skin infections. Nitrite acidified by ascorbic acid has been widely used in many studies as NO-donor system, unfortunately with inflammatory and toxic effects on the treated skin due to unregulated excessive NO generation, low pH and possible toxic side products. Here we describe an essentially modified nitrite based NO generating system that avoid the mentioned unwanted side effects on human skin by using a pH-stable acetate/acetic acid buffer with a skin neutral pH of 5.5 and sodium ascorbate. In order to overcome the shortcoming of lower NO yields due to the higher pH-value and low nitrite concentrations, we have determined additionally the influence of copper ions. To investigate the influence of different NO release and penetration kinetics on NO-induced toxicity, we have developed a fibroblast assay using cell culture plates with gas permeable bottoms. The results show clearly that the donor system can achieve a sustained NO generation without generating high peaks. Furthermore, the presence of Cu(2+) ions enhances manifold NO generation of pH/ascorbate-induced nitrite decomposition, a mechanism comprising the reduction of Cu(2+) ions to Cu(1+) by ascorbate. Finally, we have found that apart from the NO dose the NO release kinetics had a significant influence of cell toxicity. Thus, application of comparable NO amounts within a time interval of 600s led to the development of variable cell toxicities, which predominantly depended on the NO concentration values generated in the first 200s. In summary, we here describe a novel nitrite-based NO-donor system that can provide well defined NO concentrations at skin neutral pH-values for side effect poor topical dermal application, i.e. in the therapy of chronic wounds and impaired microcirculation.
Collapse
Affiliation(s)
- Christian Opländer
- Department of Plastic and Reconstructive Surgery, Hand Surgery, and Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074 Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
BACKGROUND Many different drugs have been suggested for the symptomatic treatment of primary Raynaud's phenomenon. Apart from calcium channel blockers, which are considered the drugs of choice, the evidence of the effects of alternative pharmacological treatments is limited. This is an update of a review first published in 2008. OBJECTIVES To assess the effects of various drugs with vasodilator actions on primary Raynaud's phenomenon. SEARCH METHODS For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched 14 May 2012), CENTRAL (Issue 4, 2012) and clinical trials databases. We contacted one pharmaceutical company and one trial author for additional information. In addition, the reference lists of relevant studies were searched for additional citations. There were no language restrictions. SELECTION CRITERIA Randomised controlled trials evaluating the effects of oral formulations of any drug with vasodilator effects on subjective symptoms in primary Raynaud's phenomenon. Treatment with, or comparison with, calcium channel blockers was not assessed in this review. DATA COLLECTION AND ANALYSIS Two members of the review team independently assessed the trials for inclusion and their quality and extracted the data. Data extraction included adverse events. We contacted trial authors for missing data. MAIN RESULTS Eight studies involving 290 participants were included. Two trials examined the effects of captopril, the rest were single trials on single drugs. All comparisons were with placebo. The methodological quality of most trials was poor.Enalapril was associated with a small increase in the frequency of attacks per week (difference in means 0.8; 95% CI 0.43 to 1.17). The difference between the intervention groups on a subjective improvement score was non-significant. There was a significant effect of buflomedil on the frequency of attacks per week (weighted mean difference (WMD) -8.8; 95% CI -17.55 to -0.09), but there was no evidence of effect on the severity score. The proportion with fewer attacks was significantly higher on moxisylyte than on placebo (relative risk (RR) 4.33; 95% CI 1.36 to 13.81). For captopril, beraprost, dazoxiben and ketanserin there was no evidence of an effect on the frequency, severity or duration of attacks. Beraprost and moxisylyte gave significantly more adverse effects than placebo. AUTHORS' CONCLUSIONS Poor methodological quality, small sample sizes and the limited data available resulted in low precision of the statistical results and limited value of the overall results .The overall results show that there is no evidence for an effect of vasodilator drugs on primary Raynaud's phenomenon.
Collapse
Affiliation(s)
- Marlene Stewart
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
| | | |
Collapse
|
27
|
Tanaka A, Yamazaki M, Saito M, Oh-I T, Watanabe Y, Tsuboi R. Highly sensitive high-pressure liquid chromatography with ultraviolet light method detected the reduction of serum nitrite/nitrate levels after cold exposure in patients with Raynaud's phenomenon. J Dermatol 2011; 39:889-90. [PMID: 22077642 DOI: 10.1111/j.1346-8138.2011.01433.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Manek NJ, Holmgren AR, Sandroni P, Osborn TG, Davis MD. Primary Raynaud phenomenon and small-fiber neuropathy: is there a connection? A pilot neurophysiologic study. Rheumatol Int 2011; 31:577-85. [PMID: 20035332 DOI: 10.1007/s00296-009-1293-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2009] [Accepted: 11/29/2009] [Indexed: 10/20/2022]
Abstract
The pathophysiologic factors of primary Raynaud phenomenon (RP) are unknown. Preliminary evidence from skin biopsy suggests small-fiber neuropathy (SFN) in primary RP. We aimed to quantitatively assess SFN in participants with primary RP. Consecutive patients with an a priori diagnosis of primary RP presenting to our outpatient rheumatology clinic over a 6-month period were invited to participate. Cases of secondary RP were excluded. All participants were required to have normal results on nailfold capillary microscopy. Assessment for SFN was accomplished with autonomic reflex screening, which includes quantitative sudomotor axonal reflex test (QSART), and cardiovagal and adrenergic function testing, thermoregulatory sweat test (TST), and quantitative sensory test (QST) for vibratory, cooling, and heat-pain sensory thresholds. Nine female participants with a median age of 38 years (range 21-46 years) and a median symptom duration of 9 years (range 5 months-31 years) were assessed. Three participants had abnormal results on QSART, indicating peripheral sudomotor autonomic dysfunction. Two participants had evidence of large-fiber involvement with heat-pain thresholds on QST. Heart rate and blood pressure responses to deep breathing, Valsalva maneuver, and 70° tilt were normal for all participants. Also, all participants had normal TST results. In total, three of the nine participants had evidence of SFN. The presence of SFN raises the possibility that a subset of patients with primary RP have an underlying, subclinical small-fiber dysfunction. These data open new avenues of research and therapeutics for this common condition.
Collapse
|
29
|
Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum 2009; 40:137-46. [PMID: 19878974 DOI: 10.1016/j.semarthrit.2009.08.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2009] [Revised: 08/10/2009] [Accepted: 08/24/2009] [Indexed: 10/20/2022]
Abstract
OBJECTIVES To demonstrate that unilateral digital sympathectomy, in patients with Raynaud's phenomenon (RP) and systemic sclerosis (SSc), may result in bilateral resolution of RP and digital ulcerations. METHODS We report a case of SSc and RP that had bilateral benefits from unilateral digital sympathectomy. A computer-assisted Medline/PubMed search of the medical literature was performed for 1960 through June 2009 using the keywords sympathectomy, Raynaud's phenomenon, systemic sclerosis, CREST, and digital ulcers. These searches were also combined with text words unilateral, ipsilateral, bilateral, digital sympathectomy, selective sympathectomy, autonomic nervous system, hyperhidrosis, etiology, pathogenesis, hypothesis, and treatment. Only pertinent literature, primarily in the English language, was included. RESULTS The majority of patients with SSc have RP and many suffer from digital ulcerations. Medical and behavioral management may have limited benefit and surgical intervention can be considered in recalcitrant cases, although efficacy data are sparse. We describe a man with limited SSc who underwent unilateral digital sympathectomy but manifested bilateral benefit. To our knowledge, this is the first published report of contralateral response with this procedure. The patient ultimately demonstrated these digital benefits when stressed with extreme cold and hypoxia while mountaineering. Despite the onset of high-altitude sickness and cerebral edema, his fingers remained unaffected while other mountaineers sustained severe frostbite or died of hypothermia. CONCLUSIONS Selective unilateral sympathectomy in SSc, for RP with digital ulcerations, can result in bilateral benefits despite intense challenge with cold and hypoxia.
Collapse
Affiliation(s)
- Amy Wasserman
- Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095-1670, USA
| | | |
Collapse
|
30
|
Garcia-Saura MF, Fernandez BO, McAllister BP, Whitlock DR, Cruikshank WW, Feelisch M. Dermal nitrite application enhances global nitric oxide availability: new therapeutic potential for immunomodulation? J Invest Dermatol 2009; 130:608-11. [PMID: 19812594 DOI: 10.1038/jid.2009.303] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
31
|
|
32
|
|
33
|
García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, Maldonado CG, Chávez GP, Cervera R. Treatment of Raynaud's phenomenon. Autoimmun Rev 2008; 8:62-8. [DOI: 10.1016/j.autrev.2008.07.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2008] [Accepted: 07/12/2008] [Indexed: 10/21/2022]
|
34
|
Abstract
Potential carcinogenic effects, blue baby syndrome, and occasional intoxications caused by nitrite, as well as the suspected health risks related to fertilizer overuse, contributed to the negative image that inorganic nitrite and nitrate have had for decades. Recent experimental studies related to the molecular interaction between nitrite and heme proteins in blood and tissues, the potential role of nitrite in hypoxic vasodilatation, and an unexpected protective action of nitrite against ischemia/reperfusion injury, however, paint a different picture and have led to a renewed interest in the physiological and pharmacological properties of nitrite and nitrate. The range of effects reported suggests that these simple oxyanions of nitrogen have a much richer profile of biological actions than hitherto assumed, and several efforts are currently underway to investigate possible beneficial effects in the clinical arena. We provide here a brief historical account of the medical uses of nitrite and nitrate over the centuries that may serve as a basis for a careful reassessment of the health implications of their exposure and intake and may inform investigations into their therapeutic potential in the future.
Collapse
Affiliation(s)
- Anthony R Butler
- Bute Medical School, University of St. Andrews, St. Andrews, Fife, KY16 9ST, Scotland.
| | | |
Collapse
|
35
|
Clijsen R, Taeymans J, Duquet W, Barel A, Clarys P. Changes of skin characteristics during and after local Parafango therapy as used in physiotherapy. Skin Res Technol 2008; 14:237-42. [DOI: 10.1111/j.1600-0846.2007.00270.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Abstract
BACKGROUND Many different drugs have been suggested for the symptomatic treatment of primary Raynaud's phenomenon. Apart from calcium channel blockers, which are considered the drugs of choice, the evidence of the effects of alternative pharmacological treatments is limited. OBJECTIVES To assess the effects of various drugs with vasodilator actions on primary Raynaud's phenomenon. SEARCH STRATEGY The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched 24 July 2007), and the Cochrane Central Register of Controlled Trials (CENTRAL) (last searched Issue 3, 2007). In addition, we searched MEDLINE (January 1966 to July 2007), EMBASE (1980 to July 2007) and reference lists of relevant articles. We contacted pharmaceutical companies. There were no language restrictions. SELECTION CRITERIA Randomised controlled trials evaluating the effects of oral formulations of any drug with vasodilator effects on subjective symptoms in primary Raynaud's phenomenon. Treatment with, or comparison with, calcium channel blockers was not assessed in this review. DATA COLLECTION AND ANALYSIS Both authors assessed the trials for inclusion and their quality. One author (BV) extracted the data MS checked the results. Data extraction included adverse events. we contacted trial authors for missing data. MAIN RESULTS Eight studies involving 290 participants were included. Two trials examined the effects of captopril, the rest were single trials on single drugs. All comparisons were with placebo. The methodological quality of most trials was poor. Enalapril was associated with a small increase in the frequency of attacks per week (difference in means 0.8; 95% CI 0.43 to 1.17). The difference between the intervention groups on a subjective improvement score was non-significant. There was a significant effect of buflomedil on the frequency of attacks per week (weighted mean difference (WMD) -8.8; 95% CI -17.55 to -0.09), but there was no evidence of effect on the severity score. The proportion with fewer attacks was significantly higher on moxisylyte than on placebo (relative risk (RR) 4.33; 95% CI 1.36 to 13.81). For captopril, beraprost, dazoxiben and ketanserin there was no evidence of an effect on the frequency, severity or duration of attacks. Beraprost and moxisylyte gave significantly more adverse effects than placebo. AUTHORS' CONCLUSIONS Poor methodological quality, small sample sizes and the limited data available resulted in low precision of the statistical results and limited value of the overall results . The overall results show that there is no evidence for an effect of vasodilator drugs on primary Raynaud's phenomenon.
Collapse
Affiliation(s)
- B Vinjar
- Møre and Romsdal County, Department of Health and Social Services, Fylkeshusa, Molde, Norway, 6407.
| | | |
Collapse
|
37
|
|
38
|
Abstract
Impaired cutaneous nitric oxide (NO) production is associated with diminished antioxidative capacity in skin cells, hindered wound healing, unbalanced inflammatory reactions, and disturbed immunological responses. Use of topically applied NO donors might represent an auspicious new therapeutic approach in the field of dermatology. But what is the appropriate NO-generating compound or system? In this issue, Mowbray et al. describe a new chemical inert NO donor that per se produces little inflammation in the skin.
Collapse
Affiliation(s)
- Klaus-D Kröncke
- Institute of Biochemistry and Molecular Biology I, Medical Department of the Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | | |
Collapse
|
39
|
|
40
|
Gribbe Ö, Gustafsson LE, Wiklund NP. Transdermally administered nitric oxide by application of acidified nitrite increases blood flow in rat epigastric island skin flaps. Eur J Pharmacol 2008; 578:51-6. [DOI: 10.1016/j.ejphar.2007.09.032] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2006] [Revised: 09/09/2007] [Accepted: 09/18/2007] [Indexed: 11/26/2022]
|
41
|
Mowbray M, Tan X, Wheatley PS, Rossi AG, Morris RE, Weller RB. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2007; 128:352-60. [PMID: 17914444 DOI: 10.1038/sj.jid.5701096] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Nitric oxide (NO) plays an important role in the cutaneous response to UV radiation and in cutaneous inflammation. The presence of inducible NO synthase protein in a number of inflammatory dermatoses, coupled with the induction of an intense cutaneous inflammatory infiltrate following topical application of the NO donor-acidified nitrite (NO2(-)), has set the paradigm of NO being an inflammatory mediator in human skin. Using zeolite NO (Ze-NO), a chemically inert, pure NO donor, we have shown that NO per se produces little inflammation. Biologically, relevant doses of Ze-NO induce a dermal CD4-positive T-cell infiltrate and IFN-gamma secretion. In contrast acidified nitrite, releasing equal quantities of NO (measured by dermal microdialysis and cutaneous erythema), induces an intense epidermal infiltrate of macrophages with a similar dermal infiltrate of CD3-, CD4-, CD8-, and CD68-positive cells and neutrophils. Suction blisters were created in Ze-NO-treated and control skin. IFN-gamma, but not IL-4, was detected in Ze-NO-treated skin (mean control 0.1+/-0.07 pg mg(-1) protein, mean IFN-gamma 0.6+/-0.4 pg mg(-1) protein). We suggest that the potent inflammation induced by acidified NO2(-) is secondary to the release of additional mediators.
Collapse
Affiliation(s)
- Megan Mowbray
- Department of Dermatology, University of Edinburgh, Edinburgh, UK
| | | | | | | | | | | |
Collapse
|
42
|
Carbonne B, Macé G, Cynober E, Milliez J, Cabane J. Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma. Am J Obstet Gynecol 2007; 197:e6-7. [PMID: 17689619 DOI: 10.1016/j.ajog.2007.04.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 01/06/2007] [Accepted: 04/18/2007] [Indexed: 10/23/2022]
Abstract
We report the case of a woman with scleroderma who had severe, early-onset preeclampsia on 2 consecutive pregnancies. With a treatment that included aspirin, heparin, and a nitric oxide donor, her third pregnancy ended with a healthy neonate at term. Nitric oxide donors and heparin may play a preventive role on placental dysfunction in scleroderma.
Collapse
Affiliation(s)
- Bruno Carbonne
- Department of Obstetrics and Gynecology, Hôpital Saint-Antoine, Paris, France.
| | | | | | | | | |
Collapse
|
43
|
Abstract
Nitric oxide is an endogenous gas released by endothelial cells that induces vasodilatation and plays other important roles in the wound-healing process. Nitroglycerin preparations are liberators of nitric oxide. Podiatric physicians have used nitroglycerin paste and patches on patients in an attempt to increase perfusion to the foot. However, the drug's efficacy seems to be largely anecdotal. A prospective, randomized, placebo-controlled, double-blind study was conducted to investigate the efficacy of a nitroglycerin patch in locally increasing perfusion to the foot. Twenty-two healthy subjects were randomly assigned to either a drug group (nitroglycerin patch, 0.2 mg/h) or a placebo group (adhesive patch without active ingredient). The patch was applied to the plantar arch of the foot. Objective and subjective measures were then used to detect changes in perfusion to the foot after a 2-hour experimental period. The objective measures, cutaneous thermometry and photoplethysmography, found no significant measurable difference in perfusion to the foot between the drug and placebo groups (P > .05). A subjective questionnaire used to assess changes in temperature or sensation detected by the subject yielded similar results. Thus a nitroglycerin patch dose of 0.2 mg/h showed no measurable ability to increase perfusion to the foot. Further research is needed to validate the indications for this therapy.
Collapse
Affiliation(s)
- Paul Jeong Kim
- Arizona Podiatric Medicine Program, Midwestern University College of Health Sciences, Glendale, AZ 85308, USA
| | | | | |
Collapse
|
44
|
Abstract
The availability of new treatments for Raynaud's disease, as with any medical condition, depends on how convincing the results of clinical research prove to be. The validity and reliability of research in Raynaud's disease is subject to two major constraints: the seasonal and intermittent nature of the condition limits the amount of time patients can be studied continuously, and researchers have failed to agree on objective outcome measures. Vascular physiology is, and no doubt is destined to remain, a dynamic and technology-driven clinical realm. Despite the wide array of promising treatments, the best and most basic management of Raynaud's disease seems to be behavioral and at least partly pharmaceutical. The two biggest behavioral factors are nicotine use and exposure to cold environments. Giving up nicotine can be a daunting challenge for long-term smokers and chewing-tobacco users. Avoiding cold environments may be easier said than done, especially for patients who work outdoors or in air-conditioned spaces. Perhaps the best treatment for Raynaud's disease is a reliable diagnosis and the positive prognosis that comes with it. Most patients have a stable course, and nearly half will actually improve with time and steady reassurance.
Collapse
|
45
|
|
46
|
Kingdon EJ, Mani AR, Frost MT, Denton CP, Powis SH, Black CM, Moore KP. Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma. Ann Rheum Dis 2005; 65:952-4. [PMID: 16308344 PMCID: PMC1798203 DOI: 10.1136/ard.2005.043562] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To investigate the hypothesis that increased formation of reactive nitrogen species may contribute to the vascular pathology that develops in patients with connective tissue disease such as scleroderma. PATIENTS AND METHODS The level of protein-bound nitrotyrosine in plasma was measured by stable isotope dilution gas chromatography/negative ion chemical ionisation mass spectrometry in 11 patients with primary Raynaud's phenomenon, 37 with scleroderma, 13 with chronic renal impairment, and in 23 healthy controls. RESULTS Plasma protein-bound nitrotyrosine was markedly decreased in patients with primary Raynaud's phenomenon (mean (SEM) 0.60 (0.06) ng/mg dry protein) compared with patients with scleroderma (1.78 (0.21) ng/mg protein), chronic renal impairment (1.42 (0.17) ng/mg protein) or healthy controls (1.63+/-0.15 ng/mg protein, ANOVA p<0.001). CONCLUSION These data suggest that there is decreased nitration of plasma proteins, or increased degradation of nitrated proteins from the circulation of patients with primary but not secondary Raynaud's phenomenon.
Collapse
Affiliation(s)
- E J Kingdon
- Royal Free and University College Medical School, University College London (UCL), Rowland Hill Street, London NW3 2PF, UK
| | | | | | | | | | | | | |
Collapse
|
47
|
Seabra AB, Fitzpatrick A, Paul J, De Oliveira MG, Weller R. Topically applied S-nitrosothiol-containing hydrogels as experimental and pharmacological nitric oxide donors in human skin. Br J Dermatol 2005; 151:977-83. [PMID: 15541075 DOI: 10.1111/j.1365-2133.2004.06213.x] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Nitric oxide (NO) has a wide range of functions in the skin, and topical NO donors have several potential clinical applications. However, currently available donors are either unstable on the skin surface, release low concentrations of NO, or have a short duration of action. Endogenous S-nitrosothiols (RSNOs) store and transport NO within the body and can be used as exogenous sources of NO. OBJECTIVES To study in vitro and in vivo the chemical and biological behaviour of two RSNO species, S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylcysteine (SNAC), in an easily applied hydrogel, and to correlate dermal nitrite concentration with erythema following application of the RSNOs. To assess the suitability of GSNO and SNAC as biologically effective NO donors for clinical research and as potential therapeutic agents. METHODS/PATIENTS GSNO (0.3 mol g(-1)) and SNAC (0.6 mol g(-1)) were incorporated in Synperonic F-127 hydrogels (Uniquema, Belgium). The in vitro kinetics of decomposition were measured by spectrophotometry at 37 degrees C. The RSNO-containing hydrogels were applied to the forearm skin of eight subjects. Blood flow was measured by laser Doppler for 3 h following application of NO donors and dermal nitrite simultaneously measured in microdialysate in four subjects. RESULTS The mean peak blood flow achieved was 250. At blood flow values of < 250, dermal nitrite correlated closely with blood flow and could be defined by the equation: blood flow = (nitrite concentration x 0.66) + 120, (P = 0.013). At higher blood flows there was a paradoxical fall in dermal nitrite concentration. CONCLUSIONS Topical RSNOs produce a consistent, sustained and biologically effective release of NO on human skin in vivo, which offers advantages over currently available topical NO donors. Dermal nitrite concentration--the oxidation product of NO--is directly correlated with blood flow at low and moderate levels of blood flow. At high levels of blood flow, there is a reduction in dermal nitrite, which is presumed to be due to increased blood scavenging.
Collapse
Affiliation(s)
- A B Seabra
- Instituto de Química, Universidade Estadual de Campinas, CP 6154, CEP 13084-971, Campinas, SP, Brazil
| | | | | | | | | |
Collapse
|
48
|
Abstract
The pathogenesis of Raynaud's phenomenon is not fully understood. However, the last 20 yr have witnessed enormous increases in our understanding of different mechanisms which, singly or in combination, may contribute. A key point is that Raynaud's phenomenon can be either primary (idiopathic) or secondary to a number of underlying conditions, and that the pathogenesis and pathophysiology vary between these conditions. This review concentrates upon those subtypes of Raynaud's phenomenon of most interest to rheumatologists: systemic sclerosis-related Raynaud's phenomenon, primary Raynaud's phenomenon and Raynaud's phenomenon secondary to hand-arm vibration syndrome. In this review, I shall discuss the main mechanisms thought to be important in pathophysiology under the three broad headings of 'vascular', 'neural' and 'intravascular'. While these are false distinctions because all interrelate, they facilitate discussion of the key elements: the blood vessel wall (particularly the endothelium), the neural control of vascular tone, and the many circulating factors which can impair blood flow and/or cause endothelial injury. Vascular abnormalities include those of both structure and function. Neural abnormalities include deficiency of the vasodilator calcitonin gene-related peptide (released from sensory afferents), alpha(2)-adrenoreceptor activation (possibly with up-regulation of the normally 'silent' alpha(2C)-adrenoreceptor) and a central nervous system component. Intravascular abnormalities include platelet activation, impaired fibrinolysis, increased viscosity and probably oxidant stress. As our understanding of the pathophysiology of Raynaud's phenomenon increases, so do our possibilities for identifying effective treatments.
Collapse
Affiliation(s)
- A L Herrick
- University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, UK.
| |
Collapse
|
49
|
|
50
|
Franzoni F, Plantinga Y, Femia FR, Bartolomucci F, Gaudio C, Regoli F, Carpi A, Santoro G, Galetta F. Plasma antioxidant activity and cutaneous microvascular endothelial function in athletes and sedentary controls. Biomed Pharmacother 2004; 58:432-6. [PMID: 15464871 DOI: 10.1016/j.biopha.2004.08.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2004] [Indexed: 10/26/2022] Open
Abstract
Aging is associated with endothelial dysfunction in both conduit arteries and peripheral microcirculation. Furthermore, aging is associated with an increased susceptibility to free radical mediated tissue damage. The aim of this study was to assess the relationship between age, regular aerobic-endurance training, plasma antioxidant activity and microcirculatory skin blood flow in healthy individuals. Thirty-six male athletes (range: 22-74 years; VO2max 54.3 +/- 5.2 ml/kg/min) and 36 age-sex-matched sedentary controls (range: 20-75 years; VO2max 34.2 +/- 3.4 ml/kg/min) were studied. Each group was divided into a younger (<30 years) and an older (>60 years) subgroup. Hand and foot baseline and stimulated skin blood flow (SBF) was measured by laser-Doppler flowmetry. Plasma free radicals antioxidant capacity against both peroxyl and hydroxyl radicals was also evaluated as Total Oxyradical Scavenging Capacity (TOSC) units. Baseline SBFs were not significantly different between athletes and sedentary groups, while plasma TOSC values against peroxyl radicals (18.4 +/- 3.1 vs. 13.8.0 +/- 3.4 units/ml, P < 0.001) and hydroxyl radicals (8.7 +/- 2.5 vs 4.9 +/- 2.3 units/ml, P <0.001) was higher in athletes. Hand SBF after heating and ischemia and foot SBF after heating were higher in athletes (P <0.0001) than in the sedentary group. In the sedentary groups, the lowest tertile of age had higher plasma TOSC values than the highest tertile of age (ROO- 18.2 +/- 2.2 vs 8.8 +/- 1.4 units/ml; HO- 9.2 +/- 1.3 vs 3.7 +/- 0.5 units/ml, P < 0.001). Among athletes, the lowest and the highest tertile of age did not show significantly different plasma TOSC (young: ROO- 20.3 +/- 1.5 and HO-: 9.7 +/- 1.4 units/ml; older: ROO-: 17.1 +/- 1.3 and HO-: 9.0 +/- 0.8 units/ml, n.s.). Resting SBF was similar in all the subgroups; stimulated SBFs were lower in both subgroups of untrained respect to trained individuals (P <0.001). In the sedentary subjects, SBF was inversely related to age (r = -0.63; P <0.0001) and directly related to TOSC against peroxyl (r = 0.59, P <0.001) and hydroxyl radicals (r = 0.47, P <0.01). In athletes SBF was related only to VO2max (r = 0.36; P <0.05) and TOSC vs ROO. (r = 0.41, P <0.01). In conclusion, these results suggest that regular physical activity is associated with a better microvascular endothelial function in older athletes probably due to increased antioxidant defenses.
Collapse
Affiliation(s)
- Ferdinando Franzoni
- Department of Internal Medicine, University of Pisa School of Medicine, Via Roma, 67, 56100 Pisa, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|